Im not saying it will not ever happen (If Im not mistaken Donepezil itself got provisional approval midway) but I think the change for A273 to get provisional approval is very very slim. A couple of reasons:
1. There is some belief of reform and new insight with the FDA already for 2/3 years. I dont see any sign of it. 2. The powers that be doe not permit it 3. A new kid on the block doing things differently like Anavex needs to provide solid proof.
I hope IM wrong, I really hope Im dead wrong about this!
Market Data 
Markets 
AI
